Industry News White House BioSpace
Overton FDA nomination pulled, leaving the agency under an interim chief
- The White House withdrew Heidi Overton's nomination as FDA commissioner on Tuesday evening, hours before a scheduled Senate HELP Committee vote.
- Republican senators, Democrats and some MAHA-aligned voices objected, citing her backing of an MMR-splitting executive order and reluctance to rule out advisory committee shutdowns.
- Kyle Diamantas has been interim commissioner since May, when Marty Makary left.
RBC calls it bad optics but not an operational threat, and that fits: CDER and CBER now have permanent heads, which matters more for approval timing than the commissioner's chair. The real change is political. A nominee after January 3 faces a Democratic Senate, so a long interim stretch is likely, and sponsors should price in continued policy volatility on vaccines and advisory committees rather than on review speed.
Source: BioSpace ↗ White House yanks Overton nomination hours before committee vote